New antibody drug targets Hard-to-Treat gut cancers in early trial
NCT ID NCT05411133
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 28 times
Summary
This early-stage study tested a new drug called cabotamig in 33 adults with advanced gastrointestinal cancers (like stomach, liver, or bowel cancer) that had stopped responding to standard treatments. The drug works by attaching to a marker on cancer cells and helping the immune system attack them. The main goals were to check safety and see how the drug behaves in the body, not to prove a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Queen Mary Hospital
Hong Kong, Hong Kong
-
Southern Oncology Clinical Research Unit
Adelaide, Australia
-
St George Private Hospital
Sydney, Australia
Conditions
Explore the condition pages connected to this study.